J 2021

Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries

KOLONICS-FARKAS, A. M., Martina STERCLOVA, Nesrin MOGULKOC, Katarzyna LEWANDOWSKA, Veronika MULLER et. al.

Basic information

Original name

Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries

Authors

KOLONICS-FARKAS, A. M., Martina STERCLOVA (203 Czech Republic), Nesrin MOGULKOC, Katarzyna LEWANDOWSKA, Veronika MULLER (guarantor), Marta HAJKOVA, Mordechai KRAMER, Dragana JOVANOVIC, Jasna TEKAVEC-TRKANJEC, Michael STUDNICKA, Natalia STOEVA, Simona LITTNEROVÁ (203 Czech Republic, belonging to the institution) and Martina VASAKOVA (203 Czech Republic)

Edition

FRONTIERS IN MEDICINE, LAUSANNE, FRONTIERS MEDIA SA, 2021, 2296-858X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.058

RIV identification code

RIV/00216224:14110/21:00124163

Organization unit

Faculty of Medicine

DOI

UT WoS

000745232800001

Keywords in English

IPF; treatment; regional accessibility; registry analysis; Central-Eastern Europe

Tags

Tags

International impact, Reviewed
Změněno: 15/2/2022 13:19, Mgr. Tereza Miškechová

Abstract

V originále

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with poor prognosis. The diagnosis and treatment possibilities are dependent on the health systems of countries. Hence, comparison among countries is difficult due to data heterogeneity. Our aim was to analyse patients with IPF in Central and Eastern Europe using the uniform data from the European Multipartner IPF registry (EMPIRE), which at the time of analysis involved 10 countries. Newly diagnosed IPF patients (N = 2,492, between March 6, 2012 and May 12, 2020) from Czech Republic (N = 971, 39.0%), Turkey (N = 505, 20.3%), Poland (N = 285, 11.4%), Hungary (N = 216, 8.7%), Slovakia (N = 149, 6.0%), Israel (N = 120, 4.8%), Serbia (N = 95, 3.8%), Croatia (N = 87, 3.5%), Austria (N = 55, 2.2%), and Bulgaria (N = 9, 0.4%) were included, and Macedonia, while a member of the registry, was excluded from this analysis due to low number of cases (N = 5) at this timepoint. Baseline characteristics, smoking habit, comorbidities, lung function values, CO diffusion capacity, high-resolution CT (HRCT) pattern, and treatment data were analysed. Patients were significantly older in Austria than in the Czech Republic, Turkey, Hungary, Slovakia, Israel, and Serbia. Ever smokers were most common in Croatia (84.1%) and least frequent in Serbia (39.2%) and Slovakia (42.6%). The baseline forced vital capacity (FVC) was >80% in 44.6% of the patients, between 50 and 80% in 49.3%, and 80% were registered in Poland (63%), while the least in Israel (25%). A typical usual interstitial pneumonia (UIP) pattern was present in 67.6% of all patients, ranging from 43.5% (Austria) to 77.2% (Poland). The majority of patients received antifibrotic therapy (64.5%); 37.4% used pirfenidone (range 7.4-39.8% between countries); and 34.9% nintedanib (range 12.6-56.0% between countries) treatment. In 6.8% of the cases, a therapy switch was initiated between the 2 antifibrotic agents. Significant differences in IPF patient characteristics and access to antifibrotic therapies exist in EMPIRE countries, which needs further investigation and strategies to improve and harmonize patient care and therapy availability in this region.